Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial (ID-COMET)

(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary

This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers

Study Overview

• Status: Recruiting
• Conditions: Lung Cancer; Prostate Cancer; Colo-rectal Cancer; Oligometastasis
• Intervention / Treatment: Other: Best Practice; Procedure: Stereotactic Ablative Radiotherapy

• Study Type: Interventional
• Enrollment (Estimated): 800
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: ASK RPCI; Phone Number: 1-800-767-9355; Email: askroswellpark@roswellpark.org

Study Locations

• United States
  • New York
    • Buffalo, New York, United States, 14263
      • Recruiting
      • Roswell Park Comprehensive Cancer Center
      • Contact: Phone Number: 877-275-7724; Email: askrpci@roswellpark.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 1 year or older.
• Willing to provide informed consent.
• ECOG ≤ 3.
• Life expectancy > 6 months.
• Trials 1-3: Histologically confirmed lung, prostate or colorectal malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
• Trial 4: Any malignancy with metastasis. Participants with liquid tumors are eligible provided they have biopsy confirmed refractory disease and are eligible for salvage radiotherapy.
• Newly diagnosed metastatic (1-10 sites)patients for Trials 1-3. Previously diagnosed metastatic patients (1-10 sites or oligoprogression in 5 or fewer sites with no limit on total number for Trial 4.

• Restaging completed within 12 (+/- 4) weeks prior to randomization.

  • For patients receiving thoracic radiotherapy, the enrolling physician must confirm there are no computed tomography (CT) changes suggestive of fibrotic interstitial lung disease (ILD) (i.e., reticular changes, traction bronchiectasis, or honeycombing) reported on any prior CT scans. If any are present, the patient must be assessed by a respirologist to rule out ILD prior to enrollment.
• Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry.

Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

• Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

• . Participants who have no option for standard systemic therapy or refuse systemic therapy.
• Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.
• Serious medical comorbidities precluding radiotherapy. These include ILD in patients requiring thoracic radiation, Crohn's disease in patients where the gastrointestinal (GI tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.
• For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or C); please see the Child-Pugh score calculator.

• Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix E. All such cases must be discussed with the PI or Co-I .

  • Malignant pleural effusion.

• Inability to treat all sites of disease.

  • Metastatic disease that invades any of the following: GI tract (including esophagus, stomach, small or large bowel) or skin.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or nursing female participants.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Standard Therapy followed by SABR - Trial 1-3 Arm 1	Other: Best Practice; Receive standard of care therapy; Other Names: Standard of Care; Procedure: Stereotactic Ablative Radiotherapy; Radiation therapy begins after 3 months of Standard of care; Other Names: SABER; SABR/SBRT
Experimental: SABR plus Standard therapy - Trial 1-3 Arm 2	Other: Best Practice; Receive standard of care therapy; Other Names: Standard of Care; Procedure: Stereotactic Ablative Radiotherapy; Radiation therapy begins after 3 months of Standard of care; Other Names: SABER; SABR/SBRT
Experimental: Trial 4 - Immediate SABR plus standard of care	Other: Best Practice; Receive standard of care therapy; Other Names: Standard of Care; Procedure: Stereotactic Ablative Radiotherapy; Radiation therapy begins after 3 months of Standard of care; Other Names: SABER; SABR/SBRT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival - Trial 1 and 2	Calculated from the time of randomization until death	UP to 5 years
Androgen DeprivationTherapy (ADT)-free survival - Trial 3	The time from radomization until receipt of ADT, death due to any cause, end of study or last follow up.	Up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Physician determined Radiation related toxicity	To document toxicity in patients using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 5 for each organ treated	5 years
Change in Quality of Life	Quality of life will be assessed using The EORTC Core Quality of Life questionnaire (EORTC-QLC30). This questionnaire measures cancer patients' physical, psychological and social functions. This 30 item questionnaire ranges from 1 (not at all ) to 4 (Very much) except for the global health status/quality-of-life scale, which has response options ranging from (1) "very poor" to (7) "excellent"	Up to 5 years after radiation treatment

Collaborators and Investigators

• Sponsor: Roswell Park Cancer Institute
• Investigators: Principal Investigator: Anurag Singh, MD, Roswell Park Comprehensive Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): September 18, 2024
• Primary Completion (Estimated): September 18, 2032
• Study Completion (Estimated): September 18, 2032

Study Registration Dates

• First Submitted: August 18, 2024
• First Submitted That Met QC Criteria: August 18, 2024
• First Posted (Actual): August 20, 2024

Study Record Updates

• Last Update Posted (Actual): February 4, 2026
• Last Update Submitted That Met QC Criteria: February 2, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Intestinal Diseases; Respiratory Tract Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colorectal Neoplasms; Intestinal Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Colonic Diseases; Prostatic Neoplasms; Lung Neoplasms; Colonic Neoplasms; Health Services Administration; Health Care Quality, Access, and Evaluation; Quality of Health Care; Quality Indicators, Health Care; Guidelines as Topic; Quality Assurance, Health Care; Standard of Care; Practice Guidelines as Topic
• Other Study ID Numbers: I-3739023

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes